A Phase 3 clinical trial assessing P2B001 in people with early Parkinson’s disease met its primary and a key secondary goal, with the investigative therapy showing superior efficacy to either of its two components, the approved medicines pramipexole and rasagiline, its developer, Pharma Two B, announced. Top-line trial data also…
Low levels of the hormone serotonin in the bloodstream of people with Parkinson’s disease were associated with a buildup of iron in the substantia nigra — the brain region most damaged in this disorder, a study reveals for possibly the first time. Researchers found this serotonin-iron relationship was primarily…
A Parkinson’s UK effort to bring greater racial and ethnic inclusivity to research into Parkinson’s disease is moving forward with new collaborations and a diverse steering group. The organization announced its initiative in March, aiming to improve ethnic representation in Parkinson’s investigations and clinical trials — with an early focus on Black…
IRLAB has received approval from the Swedish Medical Products Agency (MPA) to conduct a Phase 2b trial for its investigational medication, pirepemat (previously known as IRL752), which is intended to treat impaired balance and prevent falls in patients with Parkinson’s disease. “Pirepemat has potential to be the first…
According to an online survey, the COVID-19 pandemic negatively affected the caregivers of patients with Parkinson’s disease, with a large proportion of caregivers reporting feeling sadness and anxiety. The findings of the study, “COVID-19’s Impact on Burden and Nutrition for Family Caregivers of People With Parkinson’s Disease,”…
In Parkinson’s patients, greater nerve damage in the skin around the ankle is significantly associated with subsequent progression of motor symptoms, while the presence of such damage in neck skin is linked to progressive cognitive decline, a study shows. Notably, this nerve damage progression was not related to increased…
A commonly used measure of how motor symptoms are affecting daily life could also — for people in early stages of Parkinson’s disease — be taking into account the contribution of their non-motor symptoms, a study suggests. This is a likely reason for the discrepancies seen in evaluations made by patients…
Researchers have developed a highly-sensitive alpha-synuclein-based test that accurately distinguishes people with Parkinson’s from those without the disease and those with other alpha-synucleinopathies, which sometimes are difficult to distinguish based on symptoms alone. The test also was able to predict the future conversion to Parkinson’s among people with…
Argobio and GeneCode are teaming up to develop small molecules mimicking glial cell-derived neurotrophic factor (GDNF), a protein that helps nerve cells survive, for the treatment of Parkinson’s and other diseases. The collaboration builds on previous work by researchers at GeneCode, who together with Mart Saarma, PhD,…
Parkinson’s-related mutations in the LRRK2 gene, in the presence of pro-inflammatory stimuli, affect the uptake and trafficking of iron in brain cells, leading to its abnormal accumulation and “mislocalization.” That’s according to a new study in mouse models and cells derived from Parkinson’s patients, which demonstrates “altered regulation of…
Get regular updates to your inbox.
